Treatment of chronic, noninfectious, nonnecrotizing scleritis with tumor necrosis factor alpha inhibitors

Ashwinee Ragam, Anton M. Kolomeyer, Christina Fang, Yinfei Xu, David S. Chu

Research output: Contribution to journalArticlepeer-review

26 Scopus citations


Purpose: To evaluate the use of TNF-alpha inhibitors for non-infectious, non-necrotizing scleritis. Methods: We conducted a retrospective chart review of patients with non-infectious, non-necrotizing scleritis treated at our institutions from 2002 to 2012. Results: Seventeen patients (26 eyes) were included. Ten patients were started on infliximab and seven on adalimumab; five patients were treated with both TNF-alpha inhibitors on separate occasions. All patients had an associated autoimmune disease. Control of active inflammation for at least 2 months was achieved in 15 (88%) of 17 patients. Seven out of eight patients successfully tapered concurrent corticosteroid use. Only one patient discontinued TNF-alpha inhibitor use due to an allergic reaction. Conclusions: TNF-alpha inhibitors appear to have a role in managing non-infectious, non-necrotizing scleritis refractory to initial therapy, mainly by reducing inflammation and decreasing concurrent CS use.

Original languageEnglish (US)
Pages (from-to)469-477
Number of pages9
JournalOcular Immunology and Inflammation
Issue number6
StatePublished - Dec 1 2014
Externally publishedYes


  • Inflammation, noninfectious scleritis
  • TNF-alpha inhibitors

ASJC Scopus subject areas

  • Immunology and Allergy
  • Ophthalmology


Dive into the research topics of 'Treatment of chronic, noninfectious, nonnecrotizing scleritis with tumor necrosis factor alpha inhibitors'. Together they form a unique fingerprint.

Cite this